Lates News

Every AI Express, China Citic Securities released a research report on September 12th, giving Yifeng Pharmacy (603939.SH) a buy rating. The main reasons for the rating include: 1) stable development in the first half of 2025; 2) adhering to the "regional focus" strategy, with continuously increasing membership numbers; 3) continued efforts in online business, diversified innovation is expected to bring new growth to the industry. (Daily Economic News)